Clinical Evidence
This page summarizes peer-reviewed clinical trial data on GLP-1, dual-agonist, and triple-agonist weight-loss medications. The figures describe what researchers observed in those studies — not results GLP3 Weight Loss offers, promises, or provides. GLP3 Weight Loss is an independent educational resource and does not prescribe, dispense, or treat.
GLP-1 Evidence (Semaglutide — FDA-approved)
- STEP 1 Trial: 14.9% average body weight reduction reported over 68 weeks (NEJM 2021)
- STEP 2 Trial: 9.6% reduction reported in participants with type 2 diabetes (Lancet 2021)
- SELECT Trial: 20% reduction in major cardiovascular events reported (2023)
Dual Agonist Evidence (Tirzepatide — FDA-approved)
- SURPASS Trials: significant weight reduction reported in type 2 diabetes (NEJM 2021-2022)
- SURMOUNT-1: up to 22.5% weight loss reported at the highest dose (NEJM 2022)
Triple Agonist Evidence (Retatrutide — investigational, NOT FDA-approved)
- Phase 2 Trial: about 24% average weight loss reported at 48 weeks at the highest dose (NEJM 2023)
- Status: retatrutide remains in clinical trials and is not FDA-approved
All data sourced from peer-reviewed publications and framed as trial observations. Explore GLP-3 research →